Tumor-infiltrating Lymphocytes Are Significantly Associated With ...

Full text links CiteDisplay options Display options Format AbstractPubMedPMID

Abstract

Correlation between tumor-infiltrating lymphocytes (TILs) and complete pathological response (pCR) in breast cancers in neoadjuvant settings have been reported. In this study, we analyzed the association between TILs and diagnostic and prognostic parameters in estrogen receptor-positive (ER+) and triple-negative breast cancer (TNBC) without neoadjuvant treatments. Three hundred forty-four (344) patients who underwent mastectomy for breast cancer (187 ER+ and 157 TNBC) without neoadjuvant treatments were evaluated. Percentage of overall and peripheral TILs were correlated with lymphovascular invasion (LVI), Nottingham histologic grade (NHG, 1/2 versus 3), stage, lymph node status (LN), overall survival (OS), and disease-free survival (DFS). In TNBC, both peripheral and overall TILs were significantly associated with NHG 3 (P<.0001). Peripheral but not overall TILs were significantly associated with better OS (hazard ratio [HR]: 0.95; 95% confidence interval [CI]: 0.91-1.00; P=.0354) and DFS (HR: 0.95; 95% CI: 0.91-1.00; P=.0314) in univariate and multivariate analysis. In ER+ breast cancer, only peripheral TILs were associated with NHG 3 (P=.018) but not with OS or DFS (both P>.05). In ER+ breast cancer, there was a negative association between Oncotype DX recurrence score and both overall (P=.0007) and peripheral TILs (P=.0119). In conclusion, peripheral but not overall TILs correlate with better OS and DFS in TNBC, indicating the location of TILs may be important in TNBC. The negative association between TILs and Oncotype DX score in ER+ may indicate the possible prognostic value of TILs in ER+ breast cancer.

Keywords: Adjuvant therapy; Breast carcinoma; Disease-free survival; Non-neoadjuvant therapy; Overall survival; TIL; Tumor-infiltrating lymphocytes.

Copyright © 2017 Elsevier Inc. All rights reserved.

PubMed Disclaimer

MeSH terms

• Biomarkers, Tumor / analysis* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Biopsy Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Breast Neoplasms / chemistry Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Breast Neoplasms / immunology* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Breast Neoplasms / mortality Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Breast Neoplasms / surgery Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Chemotherapy, Adjuvant Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Disease Progression Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Disease-Free Survival Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Female Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Humans Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Logistic Models Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lymphatic Metastasis Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lymphocytes, Tumor-Infiltrating / immunology* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Mastectomy Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Multivariate Analysis Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Neoplasm Grading Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Neoplasm Recurrence, Local Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Neoplasm Staging Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Odds Ratio Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Predictive Value of Tests Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Proportional Hazards Models Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Receptors, Estrogen / analysis* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Risk Factors Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Time Factors Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Treatment Outcome Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Triple Negative Breast Neoplasms / chemistry Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Triple Negative Breast Neoplasms / immunology* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Triple Negative Breast Neoplasms / mortality Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Triple Negative Breast Neoplasms / surgery Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

Substances

• Biomarkers, Tumor Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Receptors, Estrogen Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information